Company: MYGN
Filing Date: 2025-04-09
Form Type: DEF 14A
Source: 0000899923-25-000028
Chunk: 3

Company: MYRIAD GENETICS INC
Filing Date: 2025-04-09
Form: DEF 14A
Chunk 3
---
 molecular diagnostic tests with strong clinical utility and an enhanced customer experience to our patients and providers in 2024.

I want to express my sincere gratitude to our customers, partners, employees, and the entire healthcare community for their trust and support. I also extend my appreciation to our stakeholders for their continued confidence in our company. Your commitment strengthens our path forward, positioning us for sustained success as we work to achieve our goals and surpass expectations. It has been an honor to serve as Myriad’s President and CEO.

#### Operational and Financial Highlights
In 2024, Myriad Genetics was recognized as one of TIME’s America’s Best Mid-Size Companies, and 84% of our teammates said Myriad Genetics is a Great Place to Work ® . As a testament to the focus and ongoing investments we have made in the patient and provider experience, our healthcare provider Net Promoter Score of 72 as of the most recent reading in July 2024, is a score that is typically regarded as excellent.

We continue to deliver on our commitment to stakeholders, having provided molecular diagnostic and precision medicine insights to more than 1.5 million patients and generated year-over-year revenue growth of 11% in 2024, marking our second consecutive year of double-digit revenue growth. A portion of our 2024 growth reflects the solid progress made by our payor and revenue cycle management teams, which contributed to a 4% increase in average revenue per test compared to the previous year. Equally important, we achieved gross-profit margin levels amongst the highest in our sector, along with positive adjusted EBTIDA and adjusted earnings per share in 2024 1 , while continuing to invest for the future.

In our Women’s Health business, we launched a new Universal Plus Panel for Foresight ® Carrier Screen in the fourth quarter of 2024, screening up to 272 genes associated with serious inherited conditions. We announced that Prequel ® Prenatal Screening test enabled by AMPLIFY TM technology is now available at eight weeks, making it the first and only prenatal cell-free DNA (cfDNA) screen available at this gestational age, which enables clinicians to offer genetic testing at the initial prenatal appointment.

We made great progress unifying our oncology offerings under our Myriad Oncology platform. We acted opportunistically to enhance the quality of our test portfolio, integrating the Precise Tumor test acquired from Intermountain Precision Genomics (IPG) in early 2024. The integration of these assets into our Salt Lake City Campus West